Harrow Health

Yahoo Finance • 18 days ago

Harrow prices $50M senior unsecured notes due 2030 at 8.625%

* Harrow (Nasdaq: HROW [https://seekingalpha.com/symbol/HROW]) on Tuesday said it priced a private offering of $50 million in senior unsecured notes due 2030, bearing interest at 8.625% per year. * The notes will be issued under the sa... Full story

Yahoo Finance • 19 days ago

A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal?

Opaleye Management Inc, a 10% Owner of Harrow(NASDAQ:HROW), reported the indirect sale of 198,572 shares of common stock in multiple open-market transactions on March 3 and March 4, 2026, for a total value of approximately $7.8 million, ac... Full story

Yahoo Finance • last month

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing

On February 17, 2026, Opaleye Management Inc. reported selling out its entire stake in Immunome(NASDAQ:IMNM), an estimated $37.30 million trade based on quarterly average pricing. What Happened According to its SEC filing dated February... Full story

Yahoo Finance • last month

Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing

Opaleye Management Inc. disclosed in a February 17, 2026, SEC filing that it sold 180,000 shares of Liquidia(NASDAQ:LQDA), an estimated $5.12 million trade based on quarterly average pricing. What Happened According to a SEC filing dated... Full story

Yahoo Finance • last month

Harrow outlines $350M–$365M 2026 revenue goal as sales force expansion and pipeline advances fuel momentum

Earnings Call Insights: Harrow, Inc. (HROW) Q4 2025 MANAGEMENT VIEW * CEO Mark Baum highlighted, “Harrow now owns one of the largest portfolios of prescription ophthalmic products in the United States market, and we have been the most... Full story

Yahoo Finance • last month

Harrow Q4 Earnings Call Highlights

Harrow logo Key Points Strong 2025 results and upbeat 2026 guide: Harrow reported Q4 revenue of $89.1M (+33% YoY) and full-year revenue of $272M (+36%), with adjusted EBITDA of $61.9M for the year; management guides 2026 revenue of $350M... Full story

Yahoo Finance • last month

Harrow (HROW) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, March 3, 2026 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Mark L. Baum President and Chief Financial Officer — Andrew R. Boll Chief Commercial Officer — Patrick Sullivan Chief S... Full story

Yahoo Finance • last month

Harrow To Launch Phase 3 Trial Of TRIESENCE In Cataract Surgery Patients

(RTTNews) - Harrow Inc. (HROW) announced that the U.S. FDA has cleared its Investigational New Drug (IND) application to support a Phase 3 clinical trial of TRIESENCE (preservative-free triamcinolone acetonide injectable suspension, 40 mg/... Full story

Yahoo Finance • last month

Harrow Q4 Net Income Slips Despite 33% Revenue Growth; Issues FY26 Guidance; Stock Down

(RTTNews) - Harrow, Inc. (HROW), an eyecare pharmaceutical company, reported fourth-quarter results with a slip in net income despite 33% higher revenue, hurt by operating and income tax expenses. In addition, the firm provided fresh guida... Full story

Yahoo Finance • last month

Here are the major earnings after the close Monday

Major earnings expected after the bell on Monday include: * Plug Power (PLUG [https://seekingalpha.com/symbol/PLUG]) * Archer Aviation (ACHR [https://seekingalpha.com/symbol/ACHR]) * Credo Technology Group Holding Ltd (CRDO [https:/... Full story

Yahoo Finance • last month

Harrow, Inc. (HROW): A Bull Case Theory

We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will summarize the bulls’ thesis on HROW. Harrow, Inc.'s share was trading at $47.69 as of February 16th. HROW’s trailing and f... Full story

Yahoo Finance • last month

Harrow Health Q4 2025 Earnings Preview

* Harrow Health (HROW [https://seekingalpha.com/symbol/HROW]) is scheduled to announce Q4 earnings results on Monday, March 2nd, after market close. * The consensus EPS Estimate is $0.47 [https://seekingalpha.com/symbol/HROW/earnings/e... Full story

Yahoo Finance • last month

These Growth Stocks Form Classic Cup Bases. Here's Where To Buy.

Two eyedrops stocks are forming cup bases on their charts and one has earnings coming up. A data center play is in a cup base buy zone. Continue Reading... Full story

Yahoo Finance • last month

TheStreet Pro: Four Stocks that Will Win Despite “Irrational Panic” over AI

The big news this week is AI may not be the economic savior that companies were hoping for. Sure, AI will help cut costs and make companies more profitable. At least, initially. What happens next is the big question. Claim 50% Off TipRank... Full story

Yahoo Finance • 4 months ago

How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story

Harrow, Inc. has secured a key win as CVS’s pharmacy benefit manager replaced Xiidra with Harrow’s dry eye drug Vevye on its Tier 1 formulary, and the company recently presented at BTIG Ophthalmology Day and the Piper Sandler Healthcare Co... Full story

Yahoo Finance • 5 months ago

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc... Full story

Yahoo Finance • 5 months ago

Harrow Health Q3 2025 Earnings Preview

* Harrow Health (HROW [https://seekingalpha.com/symbol/HROW]) is scheduled to announce Q3 earnings results on Monday, November 10th, after market close. * The consensus EPS Estimate is $0.29 [https://seekingalpha.com/symbol/HROW/earnin... Full story

Yahoo Finance • 5 months ago

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter en... Full story

Yahoo Finance • 6 months ago

13 Top Stocks With Huge Upside Potential To Buy Now

Buying stocks when the market is setting all-time highs can be a bit nerve-wracking. On the one hand, markets often continue to make new highs once they break through to new records. Conversely, nothing goes up in a straight line. After ba... Full story

Yahoo Finance • 6 months ago

Harrow, Inc. (HROW): A Bull Case Theory

We came across a bullish thesis on Harrow, Inc. on Make Money, Make Time’s Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls’ thesis on HROW. Harrow, Inc.'s share was trading at $47.88 as of September 24th. HRO... Full story